Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel
Alzamend Neuro Announces Initial Closing of Private Placement
Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million
Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program
Alzamend Receives FDA “Study May Proceed” Notification for PhIIA Trial of AL001
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced receipt of a “Study May Proceed” letter from the U.S. Food and Drug Administration (“FDA”) for the initiation of study AL001-MDD01, a Phase IIA clinical study of AL001 for treatment of patients with MDD.
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in AL001
Alzamend Neuro Announces Reverse Stock Split
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next?Generation Lithium Therapeutic Drug Candidate AL001